Are you currently taking Valproate (Epilim) for headaches?

11th December 2015

 

Are you currently taking Valproate (Epilim) for headaches?  If so, we’d like to hear from you.

The manufacturers of the drug Epilim, Sanofi wrote to Irish healthcare professionals earlier this year to advise them of new European-wide restrictions on the use of valproate in female children, adolescents, women of childbearing age or pregnant women.

MAI would like to know if your healthcare professional has informed you of the new restrictions. 

To take this survey, you should be either:

  • female and currently prescribed the drug valproate

or

  • The parent of a female child currently prescribed the drug valproate

 

Please click here to take the survey

The survey will take less than 5 minutes to complete.

 

What are the restrictions?

In late 2014, the European Medicines Agency imposed tighter restrictions on the use of  valproate in female children, adolescents, women of childbearing age or pregnant women.

The restrictions were introduced because a number of studies found developmental problems in young children exposed to valproate in the womb. Previous studies had linked valproate to increased risk of autism, ADHD and malformations such as cleft palate at birth.

Since then, the manufacturers of the drug Epilim, Sanofi have written to Irish healthcare professionals to advise them on the new restrictions and have issued patient information materials to assist medical professionals in discussing the issues with their patients.

The materials have been approved by the Health Products Regulatory Authority and have been sent to health professionals including neurologists, psychologists, GPs, family planning centres and others.

In addition to a guide for prescribers, the materials also consist of a patient information booklet (which the doctor can give to the patient) as well as a patient information form/ checklist which can be used to guide discussions between the doctor and patient and which can be stored on the patient file.

You can download the patient information booklet from the Sanofi Ireland website.

If you have any questions, please contact info@migraine.ie

Are you currently taking Valproate (Epilim) for headaches?

11th December 2015

 

Are you currently taking Valproate (Epilim) for headaches?  If so, we’d like to hear from you.

The manufacturers of the drug Epilim, Sanofi wrote to Irish healthcare professionals earlier this year to advise them of new European-wide restrictions on the use of valproate in female children, adolescents, women of childbearing age or pregnant women.

MAI would like to know if your healthcare professional has informed you of the new restrictions. 

To take this survey, you should be either:

  • female and currently prescribed the drug valproate

or

  • The parent of a female child currently prescribed the drug valproate

 

Please click here to take the survey

The survey will take less than 5 minutes to complete.

 

What are the restrictions?

In late 2014, the European Medicines Agency imposed tighter restrictions on the use of  valproate in female children, adolescents, women of childbearing age or pregnant women.

The restrictions were introduced because a number of studies found developmental problems in young children exposed to valproate in the womb. Previous studies had linked valproate to increased risk of autism, ADHD and malformations such as cleft palate at birth.

Since then, the manufacturers of the drug Epilim, Sanofi have written to Irish healthcare professionals to advise them on the new restrictions and have issued patient information materials to assist medical professionals in discussing the issues with their patients.

The materials have been approved by the Health Products Regulatory Authority and have been sent to health professionals including neurologists, psychologists, GPs, family planning centres and others.

In addition to a guide for prescribers, the materials also consist of a patient information booklet (which the doctor can give to the patient) as well as a patient information form/ checklist which can be used to guide discussions between the doctor and patient and which can be stored on the patient file.

You can download the patient information booklet from the Sanofi Ireland website.

If you have any questions, please contact info@migraine.ie